Skip to main content
search close

European Partnership on Personalized Medicine Launches 4th Transnational Call for Proposals

  • Topics

    Calls Events Funding International Research

  • Share

Image of a scientific research laboratory, featuring a microscope, laboratory equipment, and a depiction of the double helix structure of DNA on a monitor.

The 4th joint transnational call for proposals of theEP PerMed European Partnership—European Partnership for Personalized Medicine, designated CGT4PM2027, was launched on November 4 with the aim of funding transnational Research and Innovation (R&I) projects.

This call for proposals, under the theme “Cell and Gene Therapy for Personalized Medicine,” involves funding agencies from 24 European and non-European countries, including the FCT, and aims to support projects in cell and gene therapies for personalized medicine that address at least one of the following aspects:

  • Somatic cell therapies, for example, in the form of stem cells, organoids, or immune system cells;
  • Gene therapies, in the form of gene replacement, addition, or deletion therapies, using viral or non-viral vectors or employing genome editing;
  • Combined cell and gene therapies, in the form of genetically modified cells;
  • New biological products, such as mRNA, other nucleic acid-based methods, and extracellular vesicles used as delivery vehicles in gene-based therapeutic procedures.

 Preliminary proposals, corresponding to the first phase of the call for proposals, may be submitted until 1:00 p.m. (Mainland Portugal time) on January 20, 2027.

To present the competition and answer questions, an online information session will be held on December 3, 2026, from 2:00 p.m. to 4:00 p.m. Mainland Portugal time. See the detailed information about this event and register.

Co-funded under Horizon Europe, EP PerMed is a platform for the joint planning of national and European R&I support activities that implement the Strategic R&I Agenda for Personalized Medicine (2023) through dedicated funding for research, development, and innovation.

In addition to FCT, Portugal is represented in this partnership by the Agency for Clinical Research and Biomedical Innovation (AICIB), the Regional Coordination and Development Commission of the Center (CCRDC), and the Regional Directorate for Science, Innovation, and Development (DRCID) of the Autonomous Region of the Azores.

To learn about the funding conditions applicable to national entities, please visit the FCT page dedicated to the call for proposals.

Published on November 9, 2026